Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 26, 2011

View Archived Issues

Phase II SaTIS trial studies tirofiban in patients with ischemic stroke

Neurocrine Biosciences commences second phase II study of VAT2 inhibitor

Gene therapy for SCID-X1 results in sustained restoration of T-cell immunity in phase I/II trial

New 11-beta-HSD1 inhibitor shows promise to treat type 2 diabetes and complications

EMA begins review of orlistat-containing antiobesity medicines

Profectus gains access to technologies to advance rVSV-vectored vaccines

Phase I trial investigates intravenously infused oncolytic poxvirus in advanced solid tumors

SomaLogic discloses new aptamers binding to TNF receptor superfamily member 9

Japanese university patents novel antiviral glycosides

Phase II trial evaluates DCE-US to monitor response to TKI-258 therapy in renal cell carcinoma

Amakem presents new Rho-associated protein kinase inhibitors

Interim phase I data reported on AN-152 in prostate cancer

New RAR-related orphan receptor-gamma ligands claimed

FDA clears Iris' prognostic prostate cancer test

Helsinn and Eisai announce launch of phase III netupitant/palonosetron program

ALK updates on Mitizax in Europe and Japan

New trans-platinum complexes described by Spanish university researchers

Avastin approved for new indication in Japan

RegeneRx completes treatment in phase II RGN-259 study

CHMP issues opinion on Edarbi for essential hypertension

Rasitrio recommended for approval in E.U.

Medistem obtains FDA approval for clinical study of ERC stem cell product

Remicade approved in U.S. for new indication

StemCells completes first neural stem cell transplantation in phase I/II trial

Optimer Pharmaceuticals and Astellas gain CHMP recommendation for Dificid approval

Mitsubishi Tanabe Pharma obtains Japanese approval for Telavic

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ASH 2025: New blood cancer therapies trump chemo, older drugs
BioWorld
Targeted therapies and immunotherapies continue to show better results than chemotherapy in investigator-initiated and company-sponsored cancer trials, and newer...